<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>256656</rcn>
  <id>101123138</id>
  <acronym>TTT-therapy</acronym>
  <teaser>The aim of this PoC project is to commercialize new therapy for acute lymphoblastic leukemia (ALL) developed in context of my ERC consolidator grant. T-cell receptors (TCRs) have in recent years emerged as promising therapeutic molecules in cell- and gene-therapy of cancer. I...</teaser>
  <objective>The aim of this PoC project is to commercialize new therapy for acute lymphoblastic leukemia (ALL) developed in context of my ERC consolidator grant. T-cell receptors (TCRs) have in recent years emerged as promising therapeutic molecules in cell- and gene-therapy of cancer. I have completed the pre-clinical validation of a TCR that recognizes an HLA-bound peptide from a novel target, the nuclear enzyme terminal deoxynucleotidyl transferase (TdT-TCR). In vitro and in vivo data from four different mouse models show eradication of ALL and no indications of toxicity. T-cells genetically modified with the TdT-TCR effectively kill lymphoblastic cancer cells while sparing healthy B and T-cells, myeloid cells and hematopoietic stem cells. Funding has been secured for an investigator-initiated trial to determine safety and explore efficacy of TdT-TCR-T-cell therapy – TTT-therapy. The trial will recruit ALL patients relapsing from/refractory to standard therapy, who have a dismal prognosis and thus a great unmet medical need. To facilitate commercial development, I have created a start-up company and secured the company exclusive licenses for the patents on the TdT-TCR and the technology used for the development, on which I am the main inventor. In the proposed ERC PoC project, I and my strong team of advisers with expertise in the business development, clinical development, IPR and financial aspects needed for commercialization, will conduct a market analysis for TTT-therapy and develop an IPR and business strategy for the start-up company. Since several studies report expression of TdT in acute myeloid leukemia (AML), I will conduct laboratory research to determine if the TdT-TCR can also mediate killing of AML cells. AML patients have an overall 5-year survival of only 30% and hence a great medical need that potentially could be met by TTT-therapy. The described work has the potential to contribute to saving lives that would otherwise be lost to acute leukemia.</objective>
  <title>Targeting Acute Leukemia with TdT-TCR-T-cell therapy</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2023-10-01</startDate>
  <endDate>2025-03-31</endDate>
  <ecSignatureDate>2023-08-23</ecSignatureDate>
  <duration>18</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101123138</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate readOnly="true">2023-09-20 18:28:34</contentCreationDate>
  <contentUpdateDate>2023-09-20 18:28:23</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-09-19 14:48:58</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <rcn>455993</rcn>
        <id>455993-breakthrough-therapy-for-drug-resistant-leukaemia</id>
        <title>Breakthrough therapy for drug-resistant leukaemia</title>
        <contentUpdateDate>2025-04-25 09:43:19</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode readOnly="true">/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode readOnly="true">/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode readOnly="true">/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55832</rcn>
        <title>ERC-2023-POC</title>
        <identifier>ERC-2023-POC</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55832</rcn>
        <title>ERC-2023-POC</title>
        <identifier>ERC-2023-POC</identifier>
      </call>
      <organization source="corda" order="2" ecContribution="130000" terminated="false" sme="true" netEcContribution="130000" totalCost="0" type="participant">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1984179</rcn>
        <id>883757689</id>
        <legalName>TRX THERAPEUTICS AS</legalName>
        <address>
          <street>RUGLANDVEIEN 109A</street>
          <city>Eiksmarka</city>
          <postalCode>1359</postalCode>
          <country>NO</country>
          <geolocation>59.941859,10.63104</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Norway</name>
              <rcn>392333864</rcn>
              <nutsCode>NO</nutsCode>
              <euCode>NO</euCode>
              <isoCode>NO</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Norway</name>
              <rcn>392333864</rcn>
              <nutsCode>NO</nutsCode>
              <euCode>NO</euCode>
              <isoCode>NO</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <organization source="corda" order="1" ecContribution="20000" terminated="false" sme="false" netEcContribution="20000" totalCost="0" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1909023</rcn>
        <id>991104000</id>
        <vatNumber>NO993467049MVA</vatNumber>
        <legalName>OSLO UNIVERSITETSSYKEHUS HF</legalName>
        <shortName>OUS</shortName>
        <address>
          <street>KIRKEVEIEN 166 TARNBYGGET</street>
          <city>OSLO</city>
          <postalCode>0450</postalCode>
          <country>NO</country>
          <postBox>000</postBox>
          <url>http://www.oslo-universitetssykehus.no</url>
          <geolocation>60.0518829,10.6799603</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode readOnly="true">/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Oslo</name>
              <rcn>1464783</rcn>
              <nutsCode>NO081</nutsCode>
              <parents>
                <region>
                  <name>Oslo og Viken</name>
                  <rcn>1465043</rcn>
                  <nutsCode>NO08</nutsCode>
                  <parents>
                    <region>
                      <name>Norge</name>
                      <rcn>1465039</rcn>
                      <nutsCode>NO0</nutsCode>
                      <parents>
                        <region>
                          <name>Norway</name>
                          <rcn>392333864</rcn>
                          <nutsCode>NO</nutsCode>
                          <euCode>NO</euCode>
                          <isoCode>NO</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Norway</name>
              <rcn>392333864</rcn>
              <nutsCode>NO</nutsCode>
              <euCode>NO</euCode>
              <isoCode>NO</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>707186</rcn>
        <id>HORIZON_ERC-2023-POC</id>
        <code>ERC-2023-POC</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1312543</rcn>
        <id>101123138_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - TTT-therapy (Targeting Acute Leukemia with TdT-TCR-T-cell therapy)</title>
        <teaser>Acute lymphoblastic leukaemia (ALL) is a devastating blood cancer that primarily affects children and adults, often leading to relapse despite intensive treatments. Current therapies can be highly toxic and are not always effective, leaving patients with few options and a poor...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-06-17 07:52:51</sourceUpdateDate>
        <contentUpdateDate>2025-06-17 07:52:51</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225/719</code>
        <title>leukemia</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology/leukemia</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997/1613/1617</code>
        <title>enzymes</title>
        <displayCode readOnly="true">/natural sciences/biological sciences/biochemistry/biomolecules/proteins/enzymes</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode readOnly="true">/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
